about
Mirabegron: a review of recent data and its prospects in the management of overactive bladderPhysiopathology of overactive bladder syndromeEmerging pharmacological targets in overactive bladder therapy: experimental and clinical evidences[Current status of robotic urologic surgery in Italy].Urinary incontinence after radical prostatectomy: incidence by definition, risk factors and temporal trend in a large series with a long-term follow-up.Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence.[Investigational drug therapies for overactive bladder syndrome: the potential alternatives to anticolinergics].[Overactive bladder syndrome: the social and economic perspective].Patient-reported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic OnabotulinumtoxinA: 3-month results of a prospective single-armed cohort study.[Antibiotic prophylaxis in urology].Peyronie's disease: lights and shadows.Is extracorporeal shock wave lithotripsy in pediatrics a safe procedure?Advanced bladder cancer: new agents and new approaches. A review.Imaging of renal cell carcinoma: state of the art and recent advances.Imaging in prostate cancer diagnosis: present role and future perspectives.Imaging in prostate cancer staging: present role and future perspectives.Value of current chemotherapy and surgery in advanced and metastatic bladder cancer.High-intensity focused ultrasound in prostate cancer: today's outcomes and tomorrow's perspectives.Innovative pharmacotherapies for women with overactive bladder: where are we now and what is in the pipeline?Local relapse of prostate cancer after primary definitive treatment: the management.The occult urothelial cancer.Paraneoplastic Dermatomyositis Associated With Panurothelial Transitional Cell Carcinoma: A Case Report and Literature Review.Pharmacological methods for the preclinical assessment of therapeutics for OAB: an up-to-date review.Intraprostatic botulinum toxin type "A" injection in patients with benign prostatic hyperplasia and unsatisfactory response to medical therapy: A randomized, double-blind, controlled trial using urodynamic evaluation.KV7 channels in the human detrusor: channel modulator effects and gene and protein expression.High intensity focused ultrasound as first line salvage therapy in prostate cancer local relapse after radical prostatectomy: 4-year follow-up outcomes.Le infezioni delle vie urinarie.Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer.Cancer and aging: the molecular pathways.Microbiological follow-up of nosocomial infections in a single urological center.[Therapeutic strategies in penile cancer: state of the art].[An introduction to biomaterials in urology].In vitro effect of amikacin on rat and human detrusor muscle contraction.Inhibition of prostate efferent neurotransmission by amikacin.Size of bladder cancers: correlation among different types of measurement.OnabotulinumtoxinA injection therapy in men with LUTS due to primary bladder-neck dysfunction: objective and patient-reported outcomes.Objectively improving appropriateness of absorbent products provision to patients with urinary incontinence: The DIAPPER study.SOCS3 Immunohistochemical Expression Seems to Support the 2005 and 2014 International Society of Urological Pathology (ISUP) Modified Gleason Grading System.Bladder pain syndrome associated with highest impact on sexual function among women with lower urinary tract symptoms.Titanized Transobturator Sling Placement for Male Stress Urinary Incontinence Using an Inside-out Single-incision Technique: Minimum 12-Months Follow-up Study.
P50
Q24617239-177DBAC6-B95D-4687-A0D1-26E933DCA6A3Q29014461-81EE0BF2-BA64-446B-BB9C-F89F18845EB0Q29028389-F0E8FAB2-A734-4D88-BF74-DE10F9977F67Q30379850-166710E8-3FDA-477C-8A73-60C5FF1D675DQ33995726-FF1A490D-81F2-4AD3-A7CB-AA5DD1D4AC7FQ34405906-1D13455E-19CD-4992-AFB1-88BE3BB46F71Q34625226-34A691F1-C779-49F1-8C12-5D62EA87BF26Q34635059-DDFDFAD0-C064-4B85-BE40-F0B62E2F0031Q34639437-2E6129AC-5DCC-4618-8357-F92744EA3686Q35532453-BF7D9115-E8D8-46DF-9B1E-EC83D59AAFEDQ36694114-980D72C9-1A4B-487C-97D2-6B5840297A3AQ37135857-229C1914-4847-45B3-B5DC-60B3B2B76319Q37791751-B90C4CEE-5862-4574-9706-5EFFCCA3B891Q37819763-4873629A-59E3-41F1-8ED3-A02C6FCB3E9DQ37849513-FF4C52B3-94AE-4289-9E78-B39474AC8FDCQ37979650-3DADD3A5-912E-4EEE-A123-6B979B6927CDQ37987024-FF72DDA8-C9EB-4F72-B362-1D89C0C091DDQ38044471-75271751-FA64-492E-A628-7B8DD7B662DCQ38265873-5C409DF8-29CB-4691-BD9C-0CB2E13473E4Q38583811-A5D88685-5286-4D92-BEFF-C4674EE5642CQ38611212-1999BB20-5D89-4D33-AC9E-CE061E1228C3Q38680509-DBFF4872-9535-41E8-A7FB-29CDF6583FF5Q38737365-1A3884FB-C79D-4CF2-8E91-0C2E5BF1216EQ39150868-E63111C3-9F48-43AD-8CBF-AD1E275BD416Q39268777-AAAA9BFC-578B-4BC3-85C6-75BE5F511222Q40410513-5770F419-B6C6-42F0-B7C3-04274B82F69DQ41632641-64191E58-1840-4EBB-BE7C-205A95D582F0Q42168730-9CD4075E-E71D-413F-81F4-8A2DEFC26C7FQ43251364-7AC2A840-9955-414D-8F4A-36BC94ACB792Q43980553-D7610365-BD29-4916-9258-4DCCB1058A08Q45330113-B19B8354-81B9-4582-84AF-D7DCC470E1D9Q46453713-C030FC3E-4A54-49D8-81F0-1B97F4364647Q46470539-96DBB34A-DE1F-4405-8FA9-2A82E745927DQ46567579-E224166A-932F-4242-AA7C-07F527A50532Q47272779-C71366FF-A095-4DF4-BEC8-65E82A9F2503Q47978895-664335EC-F735-4AE6-847E-F4869AAEF105Q48204341-476B41AA-6ECF-4ABE-BF62-F17845323635Q48704757-A1DEB48E-EC4F-47DD-9991-6F935A810A6DQ51357890-CCB35F0D-106F-4075-AA69-BC7F92DC39F5Q51744851-D1BBC1A8-9CF3-4307-8AAD-1CC127588C70
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Emilio Sacco
@ast
Emilio Sacco
@en
Emilio Sacco
@es
Emilio Sacco
@nl
Emilio Sacco
@sl
type
label
Emilio Sacco
@ast
Emilio Sacco
@en
Emilio Sacco
@es
Emilio Sacco
@nl
Emilio Sacco
@sl
altLabel
E Sacco
@en
Sacco E
@en
prefLabel
Emilio Sacco
@ast
Emilio Sacco
@en
Emilio Sacco
@es
Emilio Sacco
@nl
Emilio Sacco
@sl
P106
P1153
22959201000
P2038
Emilio_Sacco
P21
P31
P496
0000-0003-4640-8354